lapatinib has been researched along with Response Evaluation Criteria in Solid Tumors in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baselga, J; Blackwell, K; Diéras, V; Gianni, L; Green, M; Hoersch, S; Krop, IE; Miles, D; Pegram, M; Verma, S; Welslau, M; Xu, J | 1 |
| Baron-Hay, S; Bauwens, A; Chan, A; Craft, P; de Boer, R; Kotasek, D; Redfern, A; Shannon, C; Townsend, A; Webb, S | 1 |
| Ackerman, C; Beresford, M; Berney, D; Chester, J; Chowdhury, S; Crabb, S; Elliott, T; Frew, JA; Hilman, S; Huddart, RA; Hughes, S; Hussain, S; Jagdev, S; Jones, R; Macdonald, G; Powles, T; Santhanam, S; Sarker, SJ; Stockdale, A | 1 |
3 trial(s) available for lapatinib and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Lapatinib; Male; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab; Vomiting; Young Adult | 2017 |
Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Quinazolines; Radiography; Response Evaluation Criteria in Solid Tumors; Vinblastine; Vinorelbine | 2014 |
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Humans; Lapatinib; Maintenance Chemotherapy; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Urinary Bladder Neoplasms | 2017 |